NEXPLANON (etongestrel)
Effective Date: 1/28/14
Date Developed: 1/28/14 by Robert Sterling, MD
Last Approval Date: 1/26/16, 1/24/17, 1/23/18

NEXPLANON is a progestin implant indicated for use by women to prevent pregnancy/

Authorization: for contraception

Dosing: a single implant containing 68mg of the progestin etongestrel inserted subdermally in the upper arm and replaced every three years

PRECAUTIONS: There are numerous precautions listed in the product literature, which should be consulted for details (e.g/ ectopic pregnancy, PID/sepsis, perforation, device failure, bleeding, glucose intolerance)

DRUG INTERACTIONS: Drugs or herbal products that induce enzymes that metabolize progestins (e.g/ CYP3A4) may decrease effectiveness (e.g/ barbiturates, carbamazepine, oxcarbazepine, phenytoin, St/ John’s wort)/ Variable changes in serum concentrations when used with protease inhibitors and other drugs used to treat HIV infection

REFERENCES


Revision History:

Date Reviewed/No Updates: 1/13/15 by C. Sanders, MD
Date Approved by P&T Committee: 1/27/15
Date Reviewed/No Updates: 1/26/16 by C. Sanders, MD; R. Sterling, MD
Date Approved by P&T Committee: 1/26/16
Date Reviewed/No Updates: 1/24/17 by C. Sanders, MD; R. Sterling, MD
Date Approved by P&T Committee: 1/24/17
Date Reviewed/No Updates: 1/23/18 by C. Sanders, MD; R. Sterling, MD
Date Approved by P&T Committee: 1/23/18

<table>
<thead>
<tr>
<th>Revision Date</th>
<th>Content Revised (Yes/No)</th>
<th>Contributors</th>
<th>Review/Revision Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>1/24/17</td>
<td>No</td>
<td>Catherine Sanders, MD; Robert Sterling, MD</td>
<td>Annual review</td>
</tr>
<tr>
<td>1/23/18</td>
<td>No</td>
<td>Catherine Sanders, MD; Robert Sterling, MD</td>
<td>Annual review</td>
</tr>
</tbody>
</table>